Search

Purpose: To investigate the anatomical and visual results of intravitreal dexamethasone implant treatment for macular edema secondary to retinal vein occlusion. Materials and Methods: The study included a total of 25 patients undergoing dexamethasone implant for macular edema secondary to retinal vein occlusion. Retrospective evaluation included best corrected visual acuity (BCVA) measured with ETDRS charts and macular thickness using optical coherence tomography (OCT) at each visit. The contrast sensitivity levels of patients were evaluated with Pelli-Robson chart. Results: The mean age of the patients was 59.5±13.3 years (range, 34-84years). The mean follow-up time was14.6 ± 5.5 months (range, 6-27 months) and the mean number of implants was 2.6±1.5 (range,1-6). The increase in the visual acuity according to time was statistically significant (p<0.005). The decrease in macular edema was statistically significant (p<0.005). The initial mean contrast sensitivity before implant was 0.72±0.50 log, and the final mean contrast sensitivity was 1.08±0.46 log (p<0.005). No systemic adverse events were observed in any of the cases. When the ocular adverse effects were assessed, cataract progression was seen in 54.5% and cataract operations were performed on 4 patients (18.1%). The increase in intraocular pressure was statistically significant (p<0.005) and only one patient needed medical treatment. Conclusion: Dexamethasone implant had a positive effect on anatomic and visual results in retinal vein occlusion-associated macular edema but the ideal repeat interval for intravitreal dexamethasone treatment should be shorter than 6 months. [ABSTRACT FROM AUTHOR]

Purpose. To report the efficacy of hyperbaric oxygen (HBO) therapy in a case of branch retinal artery occlusion (BRAO) in a 15-year-old boy. Methods. We report a 15-year-old boy with sudden loss of vision due to BRAO. Examination included laboratory evaluation for systemic risk factors. Follow-up exams included visual acuity, fundus examination, fundus fluorescein angiography, and visual field testing. HBO therapy was employed for treatment. Results. Medical history was positive for isolated glucocorticoid deficiency. Laboratory evaluation disclosed hyperhomocysteinemia and methylenetetrahydrofolate reductase (MTHFR) mutation. The visual acuity 0.05 at presentation improved to 0.8 after 20 days of HBO therapy. There was no change on visual fields. Conclusion. In this pediatric case, HBO therapy was useful in the treatment of BRAO. [ABSTRACT FROM AUTHOR]

Aim: It is to review the clinical features, and surgical, and visual outcomes of rhegmatogenous retinal detachment in a pediatric population. Material and Methods: Medical records of 31 children aged 16 years old or younger with rhegmatogenous retinal detachment were retrospectively analyzed. Cases of acute retinopathy of prematurity were excluded. The data for etiologies, risk factors, prior intraocular surgery, therapeutic approach options, anatomic and functional results were evaluated. Results: Thirty-three eyes of 31 patients with RRD were evaluated. The mean patient age was 11.42±3.82 years (range 3-16). There were 26 (83.9%) males and 5 (16.1%) females. The most common etiology was trauma. At presentation 57.5% of affected eyes (19/33) had a visual acuity worse than 20/400. Preoperative retinal tear was found in 60.6% (20/33) of patients. At initial examination, proliferative vitreoretinopathy was detected in 36.3% (12/33) of patients. The most common primary operation was scleral buckle with subretinal fluid drainage (69.6%, 23/33). Anatomical reattachment was accomplished in 84.8% of cases (28/33). At the final visit, 78.78% of affected eyes (26/33) had a better visual acuity when compared to preoperative examination. In nine of affected eyes (27.27%), visual acuity was 20/200 or better. Mean follow-up time was 37.5 months (range 3-72). Conclusion: In our series, pediatric RRD occurred most commonly in association with trauma. Most eyes were anatomically reattached, and most eyes retained vision of 20/800 or better. Preserving vision in children with RRD is of great importance because of high risk of vision threatening events to the fellow eye. [ABSTRACT FROM AUTHOR]

Purpose: To evaluate the safety and efficacy of gevokizumab for the treatment of Behçet's disease uveitis in a prospective, open-label, randomized phase 2 trial.Methods: Behçet's disease patients with new acute ocular exacerbation or at risk of exacerbation received 30 or 60 mg gevokizumab every 4 weeks intravenously or subcutaneously, on top of a stable regimen of immunosuppressives and corticosteroids (≤20 mg/day equivalent prednisolone). Patients withdrew in cases of ocular exacerbation.Results: A total of 21 patients were included (17 acute and 4 at-risk; mean duration of uveitis 45.6 ± 37.4 months). There were no serious adverse events related to gevokizumab. Recorded adverse events were mostly associated with exacerbation of uveitis or its complications. Response was evaluated for 14 acute patients and all showed rapid control of acute ocular exacerbation, mostly within 1 week, without any increase in corticosteroid dosage.Conclusions: Gevokizumab was well tolerated and rapidly controlled acute ocular exacerbations of Behçet's disease uveitis without the need for high-dose corticosteroid. [ABSTRACT FROM AUTHOR]